|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 777 6th Street, NW |
Address2 | Suite 510 |
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 16032-12
|
||||||||
|
6. House ID# 314630000
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Robert Billings |
Date | 01/18/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
FY 2014 Budget, FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs
H.R. 2182 Generating Antibiotic Incentives Now Act of 2011
H.R. 3026 - Safeguarding America's Pharmaceuticals Act of 2011
H.R. 3839 - Drug Shortage Prevention Act of 2012
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012
H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012
H.R. 4332 - Generic Drug Application Review Fairness Act of 2012
H.R. 5651 - Food and Drug Administration Reform Act of 2012
H.R.6160 - Stop Tampering of Prescription Pills Act of 2012
H.R. 6433 - FDA User Fee Corrections Act of 2012
H.R.6584 - Verifying Authority and Legality In Drug Compounding Act of 2012
H.R.6611 - Patient Access to Drugs in Shortage Act of 2012
H.R.6638 - S.A.F.E. Compounded Drugs Act of 2012
S. 44 Medicare Prescription Drug Negotiation Act
S. 296 and H.R.2245 Preserving Access to Life-Saving Medication Act
S. 373 Fair Prescription Drug Competition Act
S. 1584 - Drug Safety and Accountability Act of 2011
S. 1734 - Generating Antibiotic Incentives Now Act of 2011
S. 2295 - Patient Safety and Generic Labeling Improvement Act
S. 2516 - Food and Drug Administration Safety and Innovation Act
S. 3187 Food and Drug Administration Safety and Innovation Act
S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Federal Trade Commission (FTC), Food & Drug Administration (FDA), White House Office, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jim |
Fenton |
|
|
|
Jason |
Money |
|
|
|
Chris |
Davis |
|
|
|
Mark |
Hendrickson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
FY 2014 Budget, FY 2013 Budget, Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Average Manufacture Price (AMP)/AMP Publication, and generic drugs
H.R. 3342 - Affordable Medicines Utilization Act of 2011
H.R. 5651 - Food and Drug Administration Reform Act of 2012
H.R.6160 - Stop Tampering of Prescription Pills Act of 2012
H.R. 6433 - FDA User Fee Corrections Act of 2012
S. 44 Medicare Prescription Drug Negotiation Act
S. 1356 - Affordable Medicines Utilization Act of 2011
S. 2516 - Food and Drug Administration Safety and Innovation Act
S. 3187 Food and Drug Administration Safety and Innovation Act
S.1855 - Pandemic and All-Hazards Preparedness Act Reauthorization of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jim |
Fenton |
|
|
|
Jason |
Money |
|
|
|
Chris |
Davis |
|
|
|
Mark |
Hendrickson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform, Patent Settlements/Reverse Payments/Exclusionary Payments, Patent Term Extensions, Generic Drugs
H.R. 2182 Generating Antibiotic Incentives Now Act of 2011
H.R. 3497 - MODDERN Cures Act of 2011
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012
H.R. 3995 - Protecting Consumer Access to Generic Drugs Act of 2012
H.R. 4332 - Generic Drug Application Review Fairness Act of 2012
H.R. 5651 - Food and Drug Administration Reform Act of 2012
S. 27 Preserve Access to Affordable Generics Act
S. 373 Fair Prescription Drug Competition Act
S. 1734 - Generating Antibiotic Incentives Now Act of 2011
S. 1882 - The Fair and Immediate Release of Generic Drugs Act
S. 2516 - Food and Drug Administration Safety and Innovation Act
S. 3187 Food and Drug Administration Safety and Innovation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Congressional Budget Office (CBO), Federal Trade Commission (FTC), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jim |
Fenton |
|
|
|
Jason |
Money |
|
|
|
Chris |
Davis |
|
|
|
Mark |
Hendrickson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY 2014 Budget, FY 2013 Budget, Generic Drug User Fees, Funding for FDA, Funding for the Office of Generic Drugs, FY12 Presidential Budget Request, FY12 and FY13 Budget
H.R. 3988 - Generic Drug and Biosimilar User Fee Act of 2012
H.R. 5651 - Food and Drug Administration Reform Act of 2012
H.R. 6433 - FDA User Fee Corrections Act of 2012
H.J.RES.117 - Continuing Appropriations Resolution, 2013
H.RES.778 - Providing for consideration of the joint resolution (H.J. Res. 117) making continuing appropriations for fiscal year 2013
S. 2516 - Food and Drug Administration Safety and Innovation Act
S. 3187 Food and Drug Administration Safety and Innovation Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Office of Management & Budget (OMB), Congressional Budget Office (CBO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jim |
Fenton |
|
|
|
Jason |
Money |
|
|
|
Chris |
Davis |
|
|
|
Mark |
Hendrickson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Free Trade Agreements-Trans Pacific Partnership, Korean Free Trade Agreement, Anti-Counterfeiting Trade Agreement (ACTA), Generic medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, U.S. Trade Representative (USTR), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jim |
Fenton |
|
|
|
Jason |
Money |
|
|
|
Chris |
Davis |
|
|
|
Mark |
Hendrickson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |